The present invention relates to novel compounds that are inhibitors of wildtype and mutant dihydrofolate reductase (DHFR) of Plasmodium falciparum, whichare useful for the treatment of malaria. It also relates to processes of makingand using such compounds. The antimalarial compounds of the present inventionhave low toxicity to a host infected with the malarial parasite, and are potentwhen administered in pharmaceutical compositions.